The Cancer Letter

Inside information on cancer research and drug development

Guest Editorial

Mifepristone and the Administrative Procedure Act: Perspective of a former FDA commissioner and NCI director

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

This week, Federal Judge Kacsmaryk of Northern District of Texas concluded that the FDA erred in 2000 when it granted Accelerated Approval to mifepristone as an agent to facilitate a medical abortion.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Norman E. "Ned" Sharpless, MD
Professor, cancer policy and innovation, UNC Lineberger Comprehensive Cancer Center; Former director, National Cancer Institute; Former acting commissioner, Food and Drug Administration
Table of Contents

YOU MAY BE INTERESTED IN

Drugs & Targets

FDA approves new alternative standard related to mammography report assessments

FDA recently approved Alternative Standard #25 related to the Mammography Quality Standards Act. Alternative Standard #25 allows the interpreting physician to provide an assessment of “Incomplete: Need additional imaging evaluation” for the follow-up report issued within 30 calendar days of an initial report that received an assessment of “Incomplete: Need prior mammograms for comparison.”
Byline
Norman E. "Ned" Sharpless, MD
Professor, cancer policy and innovation, UNC Lineberger Comprehensive Cancer Center; Former director, National Cancer Institute; Former acting commissioner, Food and Drug Administration
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account